"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

Image credit Bladder health is often overlooked, although it is critical to our entire well-being. When your bladder do ...

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug ...

From overdoing the caffeine to skipping fermented foods, these are the food habits that can wreak havoc on our bladders. If it feels like you’re running to the loo every five minutes or can ...

UroGen Pharma has announced the dosing of the first subject in the Phase III UTOPIA clinical trial of its investigational ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

From review of the currently available trial evidence, several clinical recommendations for bladder tumor management become apparent. Transurethral resection should be done, but this procedure is ...

Self-care with overactive bladder involves making lifestyle changes, taking medications, going to physical therapy, and ...